{"id":"linsidomine","rwe":[{"pmid":"39928038","year":"2025","title":"Application of nitrates and NO-donors as a transdermal therapy for erectile dysfunction: a comprehensive review.","finding":"","journal":"Sexual medicine reviews","studyType":"Clinical Study"},{"pmid":"39907989","year":"2025","title":"Single Intraluminal Delivery of a Nitric Oxide-Donor Results in Inhibition of Intimal Thickening in the Rabbit Femoral Artery.","finding":"","journal":"Journal of vascular research","studyType":"Clinical Study"},{"pmid":"36134497","year":"2023","title":"A mechanochemical approach to the synthesis of sydnones and derivatives.","finding":"","journal":"Faraday discussions","studyType":"Clinical Study"},{"pmid":"34174140","year":"2021","title":"Continuous Monitoring Reveals Protective Effects of N-Acetylcysteine Amide on an Isogenic Microphysiological Model of the Neurovascular Unit.","finding":"","journal":"Small (Weinheim an der Bergstrasse, Germany)","studyType":"Clinical Study"},{"pmid":"33255979","year":"2020","title":"Drug-Nutraceutical Co-Crystal and Salts for Making New and Improved Bi-Functional Analgesics.","finding":"","journal":"Pharmaceutics","studyType":"Clinical Study"}],"tags":[{"label":"linsidomine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"C01DX18","category":"atc"},{"label":"Active","category":"status"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Hematologic Agents","category":"pharmacology"},{"label":"Nitric Oxide Donors","category":"pharmacology"},{"label":"Platelet Aggregation Inhibitors","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["linsidomine","linsidomine hydrochloride","linsidomine HCl"],"offLabel":[],"synonyms":["linsidomine","linsidomine hydrochloride","linsidomine HCl"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"linsidomine","explanation":"Think of it like a key that unlocks the blood vessels, allowing them to relax and widen. This helps to improve blood flow and can be beneficial for people with certain medical conditions. By releasing nitric oxide, linsidomine can help to reduce blood pressure and improve overall cardiovascular health.","oneSentence":"Linsidomine works by releasing nitric oxide, which helps to relax blood vessels and improve blood flow.","technicalDetail":"Linsidomine is a prodrug that is metabolized to its active form, which then releases nitric oxide through the action of endothelial nitric oxide synthase (eNOS). This leads to the activation of guanylate cyclase and the subsequent increase in cyclic guanosine monophosphate (cGMP) levels, resulting in smooth muscle relaxation and vasodilation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4589","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LINSIDOMINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:04:20.949649","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:51:28.658580+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"nesiritide","drugSlug":"nesiritide","fdaApproval":"2001-08-10","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"vericiguat","drugSlug":"vericiguat","fdaApproval":"2021-01-19","patentExpiry":"Nov 26, 2032","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"linsidomine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"nesiritide","brandName":"nesiritide","genericName":"nesiritide","approvalYear":"2001","relationship":"same-class"},{"drugId":"vericiguat","brandName":"vericiguat","genericName":"vericiguat","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005275","UNII":"5O5U71P6VQ","CHEBI":"CHEBI:136004","INN_ID":"6201","UMLSCUI":"C0525082","ChEMBL_ID":"CHEMBL1189150","KEGG_DRUG":"D07161","DRUGBANK_ID":"DB13400","PUBCHEM_CID":"5219","SECONDARY_CAS_RN":"16142-27-1","MESH_SUPPLEMENTAL_RECORD_UI":"C002385"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":83,"therapeuticAreas":["Hematology"],"atcClassification":{"source":"DrugCentral","atcCode":"C01DX18","allCodes":["C01DX18"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Apr 14","pmid":"39928038","title":"Application of nitrates and NO-donors as a transdermal therapy for erectile dysfunction: a comprehensive review.","journal":"Sexual medicine reviews"},{"date":"2025","pmid":"39907989","title":"Single Intraluminal Delivery of a Nitric Oxide-Donor Results in Inhibition of Intimal Thickening in the Rabbit Femoral Artery.","journal":"Journal of vascular research"},{"date":"2023 Jan 5","pmid":"36134497","title":"A mechanochemical approach to the synthesis of sydnones and derivatives.","journal":"Faraday discussions"},{"date":"2021 Aug","pmid":"34174140","title":"Continuous Monitoring Reveals Protective Effects of N-Acetylcysteine Amide on an Isogenic Microphysiological Model of the Neurovascular Unit.","journal":"Small (Weinheim an der Bergstrasse, Germany)"},{"date":"2020 Nov 26","pmid":"33255979","title":"Drug-Nutraceutical Co-Crystal and Salts for Making New and Improved Bi-Functional Analgesics.","journal":"Pharmaceutics"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"LINSIDOMINE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Linsidomine is a small molecule drug in the linsidomine class, but its target and exact mechanism of action are unknown. It is not clear if it is FDA-approved or commercially available. The drug's pharmacokinetic properties, such as half-life and bioavailability, are also unknown. Linsidomine's approved indications and generic status are not specified. Further research is needed to understand its clinical use and safety profile.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:51:28.658580+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}